Cobra Biomanufacturing has entered into an agreement with Debiopharm S.A., a Swiss drug development company, for the manufacture of the biopharmaceutical protein huTNF-Alpha Kinoid. The agreement includes process development and supply of material for clinical trials. The new agreement replaces a prior manufacturing deal with Neovacs SA that has licensed the program to Debiopharm. David Thatcher, chief executive officer of Cobra, said, “We are pleased to continue with the process development asp...